Literature DB >> 16353159

Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk.

Bernd Frank1, Kari Hemminki, Alfons Meindl, Barbara Wappenschmidt, Rüdiger Klaes, Rita K Schmutzler, Michael Untch, Peter Bugert, Claus R Bartram, Barbara Burwinkel.   

Abstract

Recently, ARLTS1 (ADP-ribosylation factor-like tumor suppressor gene 1) has been identified as a tumor suppressor gene, playing a major role in apoptotic signaling. The ARLTS1 Trp149Stop mutation has been shown to predispose to general familial cancer and high-risk familial breast cancer (BC), provoking the attenuation of apoptotic function. We studied the impact of the ARLTS1 Pro131Leu and Cys148Arg variants on high-risk familial and familial BC risk, investigating 482 familial BC cases (including 305 high-risk cases) and 530 control individuals. Unlike ARLTS1 Pro131Leu, Cys148Arg revealed a significant association with an increased risk of high-risk familial BC (odds ratio (OR)=1.47, 95% confidence interval (95% CI)=1.04-2.06, p=0.03) in a dose-dependent manner (ptrend=0.007). The genotype distribution of Cys148Arg in familial cases was similar, indicating significance as well (OR=1.48, 95% CI=1.10-1.99, p=0.009; ptrend=0.003). On the basis of the small number of 46 cases, we additionally showed an association between the Trp149Stop mutation and an increased risk of bilateral BC (OR=4.11, 95% CI=1.27-13.31, p=0.011). Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353159     DOI: 10.1002/ijc.21687

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

2.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

3.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

4.  Genetic factors and breast cancer laterality.

Authors:  Magid H Amer
Journal:  Cancer Manag Res       Date:  2014-04-16       Impact factor: 3.989

Review 5.  ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Authors:  Yan Jiang; Chen-Yang Zhao; Li-Chun Cheng; Bing Xu; Hui-Yi Lv
Journal:  Hered Cancer Clin Pract       Date:  2017-06-13       Impact factor: 2.857

Review 6.  The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective.

Authors:  Cristina Casalou; Andreia Ferreira; Duarte C Barral
Journal:  Front Cell Dev Biol       Date:  2020-04-21

7.  ARLTS1 polymorphisms and basal cell carcinoma of the skin.

Authors:  Xuchen Li; Andreas Gast; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Rajiv Kumar
Journal:  Hered Cancer Clin Pract       Date:  2007-03-15       Impact factor: 2.857

8.  ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Authors:  Sanna Siltanen; Daniel Fischer; Tommi Rantapero; Virpi Laitinen; John Patrick Mpindi; Olli Kallioniemi; Tiina Wahlfors; Johanna Schleutker
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

9.  Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls.

Authors:  Mitchell J Machiela; Weiyin Zhou; Neil Caporaso; Michael Dean; Susan M Gapstur; Lynn Goldin; Victoria L Stevens; Meredith Yeager; Stephen J Chanock
Journal:  J Hum Genet       Date:  2016-01-14       Impact factor: 3.172

10.  ARL11 regulates lipopolysaccharide-stimulated macrophage activation by promoting mitogen-activated protein kinase (MAPK) signaling.

Authors:  Subhash B Arya; Gaurav Kumar; Harmeet Kaur; Amandeep Kaur; Amit Tuli
Journal:  J Biol Chem       Date:  2018-04-04       Impact factor: 5.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.